Is Folic Acid Good for Kidney Disease?

Folic acid can be helpful for people with kidney disease, but the benefit depends heavily on the stage of disease, the specific outcome you care about, and whether you are actually deficient. A large Chinese trial found that adding folic acid to blood-pressure medication slowed the decline in kidney function, while separate studies in dialysis patients and transplant recipients showed little or no cardiovascular benefit from the same vitamin. The picture is genuinely mixed, and blanket statements in either direction miss the details that matter for individual patients.

Why Folic Acid and Kidney Disease Are Connected

Healthy kidneys help regulate the body’s levels of homocysteine, an amino acid that can damage blood vessels when it builds up. As kidney function declines, homocysteine tends to rise. Among people with end-stage kidney disease, elevated homocysteine levels are found in roughly 85 to 100 percent of patients.¹ Elevated homocysteine is considered a risk factor for blood clots and cardiovascular events, which are already the leading cause of death in people on dialysis.²

Folic acid is one of the most effective nutrients for bringing homocysteine down. It also appears to have a direct, homocysteine-independent effect on blood vessel walls, improving endothelial function through separate pathways.³ That dual action is why researchers have spent decades testing it in kidney patients. The question was never really whether folic acid lowers homocysteine in these patients (it does), but whether lowering homocysteine actually translates into fewer heart attacks, slower kidney decline, and longer survival.

Slowing Kidney Disease Progression

The strongest evidence for folic acid slowing kidney decline comes from a large substudy of the China Stroke Primary Prevention Trial, which enrolled thousands of adults with high blood pressure. Participants received either the blood-pressure drug enalapril alone or enalapril combined with 0.8 mg of folic acid daily. Those taking folic acid experienced a roughly 21 percent lower chance of kidney disease progression and a modestly slower rate of kidney function decline. Among participants who already had chronic kidney disease at the start, the benefit was more dramatic: folic acid was associated with a 44 percent slower annual decline in kidney function compared to the group receiving only enalapril.⁴

That finding is striking, but context matters. The trial took place in China, where food is not fortified with folic acid the way it is in the United States and Canada. Participants’ baseline folate levels were generally lower, which means folic acid supplementation had more room to make a difference. Whether the same benefit would show up in populations that already get substantial folate from fortified grain products is an open question.

Vitamin B12 Status Changes the Equation

A follow-up analysis of the same trial found that folic acid’s kidney-protective effect essentially disappeared in people who were deficient in vitamin B12. Among participants with adequate B12 levels, folic acid produced a large reduction in kidney disease progression. Among those with low B12, folic acid made no meaningful difference.⁵ The two vitamins work together in the same metabolic cycle, so folic acid alone may not function properly when B12 is in short supply. For anyone considering folic acid supplements for kidney health, getting B12 checked first is a practical step that the research supports.

Cardiovascular Outcomes Are Less Encouraging

Heart disease is the biggest threat for people with kidney disease, so whether folic acid prevents heart attacks and strokes matters more than almost any other endpoint. The evidence here is mixed and leans toward disappointing.

A meta-analysis pooling seven trials of folic acid in patients with advanced kidney disease found a 15 percent reduction in overall cardiovascular disease risk. The benefit was stronger when treatment lasted more than two years, when homocysteine dropped by more than 20 percent, and in countries without mandatory folic acid food fortification.⁶ However, a separate review of the available trials concluded that folic acid supplementation does not reduce the risk of heart attack or stroke in kidney disease patients and may have no effect on mortality.⁷

The disagreement likely reflects differences in which trials each analysis included, how long patients were followed, and whether participants lived in countries with food fortification. The overall message is that if folic acid does reduce cardiovascular risk in kidney patients, the effect is modest at best and may only show up under specific conditions.

Dialysis Patients and Access Clotting

People on hemodialysis have a specific concern that other kidney patients do not: keeping their vascular access from clotting. A large cohort study compared dialysis patients receiving folic acid daily versus weekly and found that daily supplementation was associated with lower rates of arteriovenous access thrombosis. However, there was no significant difference between the two groups in major cardiovascular events, overall mortality, or cardiovascular death.⁸

Dialysis also physically removes folate from the blood during each session, which is why supplementation has long been standard practice in many dialysis units. Research dating back decades has established that 1 mg of folic acid daily, or even 1 mg after each dialysis session, is enough to maintain adequate folate levels in most patients.⁹ That dose is well above the general adult recommendation but reflects the reality that dialysis strips water-soluble vitamins out of the bloodstream.

Kidney Transplant Recipients

After a kidney transplant, homocysteine levels often remain elevated. The FAVORIT trial, one of the largest studies in this population, tested whether a high-dose multivitamin containing folic acid, vitamin B6, and vitamin B12 could reduce cardiovascular events in transplant recipients. Despite successfully lowering homocysteine, the high-dose vitamin group had no reduction in cardiovascular events, no improvement in survival, and no protection against return to dialysis compared to a low-dose control group.¹⁰ This result reinforced a recurring theme in the broader folic acid research: lowering homocysteine numbers does not automatically produce better clinical outcomes.

Folic Acid and Anemia in Kidney Disease

Anemia is extremely common in chronic kidney disease because the kidneys produce less erythropoietin, the hormone that stimulates red blood cell production. Most patients receive synthetic erythropoietin injections. Since folate is needed to build new red blood cells, it would seem logical that supplementation would help these patients respond better to erythropoietin therapy.

In practice, the benefit depends entirely on whether the patient is actually folate-deficient. Among dialysis patients with macrocytic anemia (a type linked to folate or B12 deficiency), high-dose folic acid supplementation raised hemoglobin levels and even allowed lower erythropoietin doses. But in patients whose red blood cells were already normal-sized, folic acid supplementation made no difference in their response to erythropoietin.¹¹ A broader review of folate metabolism in kidney failure came to the same conclusion: unless patients have clear folate depletion, extra supplementation does not improve red blood cell production or the response to erythropoietin therapy.¹²

Interestingly, the updated 2026 KDIGO clinical guideline for anemia in kidney disease no longer includes folate assessment as part of the routine initial workup. The guideline does note, however, that folate stores can drop during erythropoietin treatment and that dialysis efficiently clears folate from the blood, so monitoring may still be warranted in certain patients.¹³

Diabetes and Kidney Damage

Diabetic kidney disease is the leading cause of kidney failure worldwide, so any intervention that might slow it deserves attention. The evidence here is a genuine contradiction.

In the same Chinese hypertension trial discussed earlier, folic acid had its biggest impact among participants who had diabetes. Diabetic patients who received folic acid plus enalapril had roughly half the rate of new proteinuria (protein in the urine, a key marker of kidney damage) compared to those on enalapril alone, and their kidney function declined about 55 percent more slowly.¹⁴ However, a randomized trial in European patients with established diabetic nephropathy found that high-dose folic acid did not improve kidney blood vessel function and did not reduce albuminuria.¹⁵

The difference may come down to timing. The Chinese trial enrolled patients who did not yet have kidney damage and was measuring prevention. The European trial enrolled patients who already had established kidney disease. Folic acid may help prevent early diabetic kidney damage rather than reverse damage that already exists, though this remains unproven.

Dietary Folate and Prevention

Most of the research discussed so far involves folic acid supplements given to people who already have kidney disease. A separate question is whether getting enough folate through food might help prevent kidney disease from developing in the first place.

A 30-year follow-up study that tracked adults from young adulthood into middle age found a clear association between higher dietary folate intake and lower risk of developing chronic kidney disease. The relationship followed an L-shaped curve: risk dropped sharply as intake rose from very low levels, then leveled off. People in the middle and upper ranges of folate intake had roughly 60 to 65 percent lower risk of developing kidney disease compared to those with the lowest intake.¹⁶ This is observational data, so it cannot prove that folate itself was responsible, but the consistency across 30 years of follow-up is noteworthy.

A cross-sectional analysis of U.S. adults also found that higher serum folate was associated with lower odds of diabetic kidney disease. But the same study revealed something unexpected: elevated levels of unmetabolized folic acid in the blood, which happens when you take more synthetic folic acid than your body can convert, were actually associated with a higher risk of diabetic kidney disease.¹⁷ The distinction between well-metabolized folate and excess unmetabolized folic acid may be important, and it raises the question of whether food-derived folate is preferable to high-dose supplements for long-term kidney protection.

Genetics and Who Responds Differently

Not everyone processes folic acid the same way. A common genetic variant in the MTHFR gene (which encodes the enzyme that converts folic acid into its active form) can significantly affect how well you use folate. Research has found that people with certain MTHFR variants, particularly the C677T mutation, face higher mortality risk when they have advanced kidney disease. In patients with end-stage kidney disease, carrying two copies of the variant was associated with more than double the risk of death.¹⁸

Separately, a study of dialysis patients found that MTHFR variants were less common among people who had reached end-stage kidney failure, suggesting the gene may have a complex, possibly protective relationship with kidney function earlier in the disease course.¹⁹ People with these variants may need the already-active form of folate (methylfolate) rather than standard folic acid, though clinical trials have not yet confirmed this in kidney patients specifically.

Children on Dialysis

Pediatric kidney disease brings its own nutritional challenges. Children with early-stage kidney disease generally need the same folate as healthy children of the same age. But for children on dialysis, the picture changes. Because dialysis strips water-soluble vitamins out of the blood just as it does in adults, supplementation with folate, vitamin B6, and vitamin C may be needed to prevent deficiency. Expert guidelines from the Pediatric Renal Nutrition Taskforce recommend that vitamin requirements for children with advanced kidney disease may differ from those of healthy children and should be monitored accordingly.²⁰

Active Folate and Acute Kidney Injury

An emerging area of research involves 5-methyltetrahydrofolate (5-MTHF), the form of folate that your body actually uses after converting folic acid. Animal research on acute kidney injury has shown that a low dose of 5-MTHF improved kidney function and reduced oxidative stress by activating antioxidant defense pathways in kidney tissue.²¹ This is preliminary work in animals, not a treatment recommendation. But it points to the possibility that folate’s benefits for the kidneys go beyond homocysteine lowering and involve direct protection of kidney cells from damage. Whether this mechanism matters at the doses humans typically take remains to be seen.

On the other side of the dose spectrum, extremely high injected doses of folic acid are actually used in lab mice as a standard method for causing kidney injury. When researchers combined this folic acid injury model with a high-fat diet, the kidney damage was substantially worse, with increased inflammation and reduced mitochondrial function.²² This does not mean oral folic acid supplements are dangerous. The doses used in these experiments are vastly higher than anything a person would take. But it does illustrate that folic acid, like many nutrients, follows a dose-response curve where massive excess can cause harm, and that metabolic context such as obesity can influence how the body handles it.

When Folic Acid Likely Does Not Help

Several scenarios consistently fail to show benefit. Combining folic acid with vitamins B6 and B12 has not reduced cardiovascular complications or mortality in kidney disease patients across multiple studies. The FAVORIT trial in transplant recipients, discussed earlier, is the largest example. The pattern suggests that simply driving homocysteine down with B vitamins is not enough once cardiovascular disease is already established or well advanced.

Similarly, in countries where grain products are fortified with folic acid, most people already have adequate folate levels, which narrows the window for supplementation to help. The cardiovascular benefit seen in the meta-analysis of kidney disease trials was driven largely by studies conducted in regions without mandatory fortification.⁶ If you live in the U.S., Canada, or another country that adds folic acid to flour, you may already be getting enough for the vitamin to have done whatever good it can do.

People with established, advanced diabetic nephropathy also showed no kidney-specific benefit from high-dose folic acid in a controlled trial, despite the supplement’s promise in earlier-stage disease.¹⁵ Once significant kidney scarring has occurred, a vitamin supplement is unlikely to reverse structural damage.

Practical Considerations for Patients

If you have kidney disease and are wondering whether to take folic acid, a few practical points emerge from the research. First, your folate and B12 levels matter. Folic acid is most likely to help people who are actually deficient or have suboptimal levels, and B12 deficiency can block folic acid from working. Second, if you are on dialysis, routine folic acid supplementation is reasonable because dialysis removes it from your blood. Third, the strongest evidence for kidney protection comes from people with high blood pressure and earlier-stage disease, not from people with advanced kidney failure. Fourth, food fortification changes the calculus. If you eat a typical diet in a country with mandatory fortification, your folate levels are probably adequate, and extra supplementation may offer diminishing returns. Finally, the form of folate may matter. Accumulating unmetabolized folic acid in the blood has been associated with unfavorable outcomes in at least one large population study, which is worth discussing with a doctor before taking high doses of the synthetic form.